Mylan Announces Pricing of Add-On Offering of Se... (t be registered under the Securities Act...)

Mylan Announces Pricing of Add-On Offering of Senior Notes

Date:7/30/2010

t be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to Mylan's failure to consummate the private placement or to utilize the proceeds of such placement as described in this press release. T
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
2. Mylan Announces Settlement Agreement for Namenda®
3. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
4. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
5. Mylan Receives Approval for Nabumetone Tablets
6. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
7. Mylan Receives Approval for Generic Version of Arimidex® Tablets
8. Mylan Receives Approval for Generic Version of Zocor® Tablets
9. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
10. Mylan Receives Approval for Generic Version of Neurontin® Tablets
11. Mylan Receives Approval for Generic Version of Valtrex®

Post Your Comments:

(Date:5/24/2013)... LOS ANGELES , May 24, 2013 An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 2 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...

... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...

Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4

First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim

(Date:5/24/2013)... NY (PRWEB) May 24, 2013 ... (AICASA) has signed an articulation agreement with ... students to study abroad in Antigua. , ... college credits after participating in a cell biology course, ... articulation agreement with American University of Antigua (AUA) ...

(Date:5/24/2013)... (PRWEB) May 24, 2013 The ... of products used outside the central laboratory, by ... a healthcare practitioner or by consumers. This includes ... fertility and pregnancy, infectious and cardiovascular disease and ... such as critical care, surgical and emergency departments. ...

(Date:5/24/2013)... than half of recommended well-child visits had up to ... attended most of their visits, according to a study ... Care . The study included more than 20,000 children ... chronic conditions like asthma and heart disease were even ... according to the study. In fact, children with ...

(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...

(Date:5/24/2013)... presented today shows that formation of new neurons in ... importance in learning and remembering - could cause forgetting ... brain circuits. Drs. Paul Frankland and Sheena Josselyn, ... argue this reorganization could have the positive effect of ... for new learning. These results were presented at ...

Breaking Medicine News(10 mins):Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2 Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2 Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3 Health News:Young children who miss well-child visits are more likely to be hospitalized 2 Health News:Young children who miss well-child visits are more likely to be hospitalized 3 Health News:Proteins in migration 2 Health News:Proteins in migration 3 Health News:Proteins in migration 4 Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2

[0] AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program [0] Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com [0] Young children who miss well-child visits are more likely to be hospitalized [0] Proteins in migration [0] New neuron formation could increase capacity for new learning, at the expense of old memories

... the 13th time, more than any hospital in the U.S. , ... ... (NorthShore) was named one of the nation,s 100 Top Hospitals® by Thomson ... and quality of healthcare. NorthShore has been named a Top 100 Hospital ...

... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...

... KUALA LUMPUR, Malaysia, March 31 Rheumatoid arthritis (RA) ... which the body,s defense system attacks the joints through ... lines and lubricates the joints. The most visible symptoms ... of the hands and feet. It can cause fatigue, ...

... LifeCare Holdings, Inc. (the "Company") today announced its operating ... 2008. Three Months Ended December 31, 2008 ... service revenue of $94.2 million for the three months ended ... the same period in 2007 while patient days were unchanged. ...

... Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE CITY, ... and the American Association for Clinical Chemistry ... for a key laboratory method called qPCR (or quantitative ... international scientists representing the medical and research fields. qPCR ...

... The U.S. District Court for the District of ... between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. ... markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the ... valid or infringed by the filing of Andrx,s Abbreviated ...

NorthShore University HealthSystem Named One of the Nation's Top 100 Hospitals by Thomson Reuters Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia LifeCare Holdings, Inc. Announces Year-End Results International Scientists Secure Quality in Molecular Diagnostics District Court Decision Received in CONCERTA(R) Patent Case

VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....

VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...

VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...

VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...

Medicine Products:

VascoTip CC 9/60 M VascoScrew E D10/60 M VascoTwist CC 9/60 S VascoScrew P 8/60 S